Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Kanion Pharmaceutical Co (SHSE:600557) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jiangsu Kanion Pharmaceutical Co EBITDA Margin % Related Terms
Jiangsu Kanion Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Kanion Pharmaceutical Co EBITDA Margin % Chart
SHSE:600557 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Kanion Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Kanion Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Kanion Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jiangsu Kanion Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Kanion Pharmaceutical Co (SHSE:600557) has a EBITDA Margin % of 12.13% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Kanion Pharmaceutical Co and its competitors. This is 26% below median its historical median of 16.41. Over the past decade, Jiangsu Kanion Pharmaceutical Co's EBITDA Margin % has ranged from 11.24 to 20.36. According to the industry distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #509 out of 961 companies in the Drug Manufacturers industry, placing it in the top 53%.
Is Jiangsu Kanion Pharmaceutical Co's EBITDA Margin % too high?
Jiangsu Kanion Pharmaceutical Co's current EBITDA Margin % of 12.13% is 26% below median its 10-year median of 16.41. Over the past 10 years, this metric has ranged from a low of 11.24 to a high of 20.36. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Jiangsu Kanion Pharmaceutical Co's value of 12.13% is 2.9% below this industry median. Based on the distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #509 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jiangsu Kanion Pharmaceutical Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Kanion Pharmaceutical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #509 out of 961 companies for EBITDA Margin %. This places Jiangsu Kanion Pharmaceutical Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Jiangsu Kanion Pharmaceutical Co's value of 12.13% is 2.9% below this benchmark. Historically, Jiangsu Kanion Pharmaceutical Co's own EBITDA Margin % has ranged from 11.24 to 20.36 over the past decade. While the company's 10-year median is 16.41 vs. the industry median of 12.49, Jiangsu Kanion Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Kanion Pharmaceutical Co's current EBITDA Margin % of 12.13% is 2.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jiangsu Kanion Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Kanion Pharmaceutical Co's current EBITDA Margin % is 12.13%, which is 26% below median its own 10-year median of 16.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Kanion Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Kanion Pharmaceutical Co (SHSE:600557) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.70, compared to a current price of ¥13.63 — trading 0.5% below its estimated fair value. The current EBITDA Margin % is 12.13%, which is 26% below median its 10-year median of 16.41 and 2.9% below the Drug Manufacturers industry median of 12.49. Jiangsu Kanion Pharmaceutical Co's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jiangsu Kanion Pharmaceutical Co (SHSE:600557), the current EBITDA Margin % is 12.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Kanion Pharmaceutical Co (SHSE:600557) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Kanion Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥13.63 is trading 0.5% below its estimated GF Value™ of ¥13.70.
GuruFocus considers Jiangsu Kanion Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600557:
EBITDA Margin %: 12.13% (26% below median its 10-year median of 16.41)
GF Value™: ¥13.70 vs. price of ¥13.63 (0.5% below fair value)
Industry Position: 2.9% below the Drug Manufacturers median (#509 of 961)
No single metric tells the full story. See the SHSE:600557 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Kanion Pharmaceutical Co Business Description
Jiangsu Kanion Pharmaceutical Co Ltd focuses on R&D, production and trade of traditional Chinese medicine. The company also makes orthopedics, cardiovascular, anti-infective and anti-tumor products.
82GF Score
Get the complete analysis for SHSE:600557
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600557 has been successfully added to your 
